|
1 2 3 4 5 6
читать далее ... ффект в 57%, стабилизацию в 21%, с медианой времени до прогрессирования - 14 мес. Высокая избирательная эффективность Кселоды, низкий токсический профиль, удобство применения позволят ей занять передовые позиций в.современной химиотерапии злокачественных новообразований. Литература 1. Kondo К, Chin К, Sakamoto J, et al. Modified capecitabine regimen for advanced/metastatic gastric cancer: final results from multicenter phase II trial. Eur J Cancer 2003; 1(suppl.5):S69 (Abstr 221). 2. Koizumi W, Saigenji K, Ujiie S, et al. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 2003; 64:232-6. 3. Hong YS, Song SY, Lee Sl et al. A phase II trial of capecitabine in previously untreated patients with advanced or metastatic gastric cancer. Ann Oncol 2004; 15:1344-7. 4 Leon-Rodriguez E, Green D, Candelaria M, et al. Oral capecitabine in treatment of patients with advanced or metastatic gastric carcinoma. Ann Oncol 2002; 13(Suppl.5): 191 (Abstr 708P). 5 Kim TW, Kang YK, Ahn JH, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 2002; 13:1893-8. 6.Evans TR, Pentheroudakis G, Paul, et al. A phase I and pharmacokinetics study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Ann Oncol 2002; 13: 1469-78. 7. Jackson DP, Smith D, Topham CA, et al. Fortnightly intravenous irinotecan plus oral capecitabine as treatment for gastroesophageal cancer - a phase 1 and 2 study. Eur J Cancer 2003; 1 (Suppl.5): S64 (Abstr 206). 8. Petrovic Z, Tarabar D, Doder R, et al. Oxaliplatin (L-OHP) and capecitabinef X ) as second line chemotherapy in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 2003;22;299 (Abstr 1199). 9. Yeon Нее P, Choi S-J, Ryoo B-Y, Kim H. A prospective phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 2003:22:307 (Abstr 1232). 10. Shin DB, Cho EK, Lee W, et al A phase II trial of epirubicin (E), cisplatin © and capecitabine (X) combination chemotherapy for previously untreated advanced gastric cancer (AGC).. Ргос.Агп Soc Clin Oncol 2003:22:318 (Abstr 1318). 11. Kang HJ. A phase II study of paditaxel and capecitabine combination chemotherapy in patients with advanced gastric cancer as a first-line therapy. Proc Am Soc Clin Oncol 2004;23 (Abstr 4051). 12. KangY-K, KimTW, Chang HM, etal. A phase 1/11 study of docetaxel, capecitabine and cisplatin as a first line chemotherapy for advanced gastric cancer. Proc Am Soc Clin Oncol 2004;23 (Abstr 4066). 13.Kim TW, Kang YK, Ahn JH, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 2002; 13:1893-8 14. Jin M, Shen L, Ни В. Capecitabine combined with cisplatin in patients with advanced gastric carcinoma (AGC) a Chinese phase II study.. Proc Am Soc Clin Oncol 2003:22:318 (Abstr 1279),Источник: Маркович А.А., Горбунова В.А. Русский медицинский журнал. 2006. Т.14. №14. С.1016-1019
|
